Onto Innovation vs Vaxcyte Inc. Common Stock — how do they compare? Onto Innovation trades at $232 (market cap $12.93B), while Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B). The key difference: Onto Innovation is the larger of the two by market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Onto Innovation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Onto Innovation for 7 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| ONTO | PCVX | |
|---|---|---|
Market Cap | $12.93B | $10.51B |
Volume | 1,098,259 | 2,644,694 |
Sector | Technology | Health |
52-Week High | $378.45 | $73.82 |
52-Week Low | $124.09 | $40.32 |
Typical Hold Time | 7 Days | 0 Days |
Enterprise Value | $12.52B | $9.14B |
Signals from Pluang's Aura AI — not financial advice
ONTO trades at $263.55, down 3.72% with bearish technical signals but strong analyst support. The stock shows mixed earnings performance with a Q2 2026 beat but misses in prior quarters. Revenue grew to $1.01B in 2025 with 11.84% net margin, though valuation remains elevated at P/E 98.71. Recent news highlights a $1.1B backlog and strategic partnerships in semiconductor manufacturing.
Outlook remains positive with 100% analyst buy ratings and $387 consensus target suggesting 47% upside. Key risks include high valuation multiples and semiconductor cycle volatility. Growth catalysts include AI-driven demand and Dragonfly G5 product momentum, though execution on backlog conversion is critical.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Onto Innovation provides process control solutions for semiconductor manufacturing. Its inspection and metrology systems help chipmakers measure, analyze, and detect defects on wafers and advanced packages.
Read more on ONTO →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →